Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.

Toxicity, biodistribution and persistence of candidate HIV vaccines pTHr.HIVA, a recombinant DNA, and MVA.HIVA, a recombinant modified vaccinia virus Ankara, were determined in the Balb/c mouse. The mice were injected with either two doses of intramuscular pTHr.HIVA DNA (50 microg each, separated by...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Hanke, T, Mcmichael, A, Samuel, R, Powell, L, McLoughlin, L, Crome, S, Edlin, A
Format:	Journal article
Język:	English
Wydane:	2002

Podobne zapisy

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
od: Hanke, T, i wsp.
Wydane: (2005)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
od: Schmidt, C, i wsp.
Wydane: (2008)

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
od: Peters, B, i wsp.
Wydane: (2007)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
od: Jeffrey R Currier, i wsp.
Wydane: (2010-11-01)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
od: L. F. Stovba, i wsp.
Wydane: (2023-04-01)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
od: Howles, S, i wsp.
Wydane: (2010)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
od: Alina Tscherne, i wsp.
Wydane: (2024-11-01)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
od: Dorrell, L, i wsp.
Wydane: (2007)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
od: M. F. Ferrer, i wsp.
Wydane: (2007-09-01)

Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
od: Lioba Klaas, i wsp.
Wydane: (2021-10-01)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
od: Volker Sandig, i wsp.
Wydane: (2013-01-01)

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
od: Wee, E, i wsp.
Wydane: (2002)

A Novel Monoclonal Antibody Against a Modified Vaccinia Ankara (MVA) Envelope Protein as a Tool for MVA Virus Titration by Flow Cytometry
od: Simeon Cua, i wsp.
Wydane: (2024-10-01)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
od: Cottingham, M, i wsp.
Wydane: (2008)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
od: Matthew G Cottingham, i wsp.
Wydane: (2008-02-01)

Development of a DNA-MVA/HIVA vaccine for Kenya.
od: Hanke, T, i wsp.
Wydane: (2002)

Expression of an Efficient Selection Marker Out of a Duplicated Site in the ITRs of a Modified Vaccinia Virus Ankara (MVA)
od: Sirine Abidi, i wsp.
Wydane: (2024-12-01)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
od: Maurilia Marcacci, i wsp.
Wydane: (2020-07-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
od: Lior Nave, i wsp.
Wydane: (2023-08-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
od: Matthew G. Cottingham, i wsp.
Wydane: (2011-01-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
Wydane: (2011-01-01)

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
od: Estcourt, M, i wsp.
Wydane: (2005)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
od: Rachael Chiam, i wsp.
Wydane: (2009-06-01)

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells.
od: Chen Peng, i wsp.
Wydane: (2020-08-01)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
od: Jaoko, W, i wsp.
Wydane: (2008)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
od: Hanke, T, i wsp.
Wydane: (2007)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
od: Mwau, M, i wsp.
Wydane: (2004)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
od: Maria L Knudsen, i wsp.
Wydane: (2015-01-01)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
od: Ondondo, B, i wsp.
Wydane: (2013)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
od: Ondondo, B, i wsp.
Wydane: (2013)

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
od: Juan García-Arriaza, i wsp.
Wydane: (2011-01-01)

Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs
od: Busquets, N, i wsp.
Wydane: (2011)

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.
od: Ruikang Liu, i wsp.
Wydane: (2019-05-01)

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
od: Julie Delaloye, i wsp.
Wydane: (2009-06-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
od: Juan García-Arriaza, i wsp.
Wydane: (2021-08-01)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
od: Dorrell, L, i wsp.
Wydane: (2000)

Retraction: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
od: The Editors
Wydane: (2022-01-01)

Notes on Transient Host Range Selection for Engineering Vaccinia Virus Strain MVA
od: David C. Tscharke, i wsp.
Wydane: (2002-07-01)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
od: Patricia Pérez, i wsp.
Wydane: (2020-02-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
od: Hanke, T, i wsp.
Wydane: (1998)